First most-favored-nation drug pricing deal announced, opening run of 16 agreements
The first of 16 most-favored-nation pricing deals lowered direct prices for drugs including Ozempic, Wegovy and Zepbound, with details on eligibility still undisclosed.
The first of the Trump administration's most-favored-nation drug pricing agreements with a pharmaceutical manufacturer was announced on September 30, 2025, opening a run of deals that the White House said reached 16 companies by February 2026 [1].
Most-favored-nation, or MFN, pricing means paying prices in line with the lowest paid by other developed nations [1]. The White House fact sheet announcing the February 5, 2026 launch of TrumpRx.gov says that "since September 30, 2025, President Trump has announced 16 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations" [1]. The fact sheet does not name the company that signed the first agreement.
The first five manufacturers to reach MFN deals were AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer, and their drugs were the ones featured when TrumpRx.gov launched [1]. Drugs from other companies that have signed MFN deals will be added to the site "in the coming months," according to the fact sheet [1].
At launch, the site listed reduced prices on 40 branded medicines [1]. For the GLP-1 drugs, the fact sheet gives these monthly figures: Ozempic from $1,028 to an average of $350 and as low as $199, depending on dosage strength; injectable Wegovy from $1,349 to the same range; the Wegovy pill from $1,349 to as low as $149; and Zepbound from $1,088 to an average of $346 and as low as $299 [1]. Ozempic and Wegovy contain semaglutide; Zepbound contains tirzepatide.
The same announcement listed other reductions: the fertility drug Gonal-F at as low as $168 per pen, Cetrotide from $316 to $22.50, and Ovidrel from $251 to $84, with average savings of more than $2,000 per cycle of fertility drugs for patients who pay out of pocket [1]. The COPD inhaler Bevespi Aerosphere was listed from $458 to $51, the asthma inhaler Airsupra from $504 to $201, the topical ointment Eucrisa for atopic dermatitis from $792 to $158, Insulin Lispro at as low as $25 per month, and Duavee from $202 to $30 [1].
The fact sheet traces the policy to an executive order signed May 12, 2025, "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," and letters sent to manufacturers on July 31, 2025 [1]. It also cites a December 1, 2025 agreement with the United Kingdom that the administration says will raise the net price of new prescription drugs there by 25%, and a January 15, 2026 call for Congress to pass what the White House calls The Great Healthcare Plan, which the administration says would codify the MFN savings [1].
Why it matters for patients
The prices listed are for patients with valid prescriptions who buy directly through TrumpRx.gov, using coupons they print or download, or through channels set up by manufacturers and integrated into the site [1]. The fact sheet does not say whether these prices apply to people using insurance, Medicare or Medicaid, how long the prices will remain in effect, or what eligibility rules apply beyond having a prescription. Prices vary by dosage strength [1].
For adults taking semaglutide or tirzepatide, the announced monthly figures are far below the earlier prices cited in the announcement [1]. Whether a given patient pays those amounts depends on details the fact sheet does not address.
What happens next
The fact sheet says additional drugs from other manufacturers that signed MFN deals will be made available through TrumpRx.gov in the coming months [1]. It does not name which products or companies come next. The White House also says it asked Congress on January 15, 2026 to codify the MFN savings in legislation [1]; no timeline for that has been disclosed.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.